Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03690115
Recruitment Status : Recruiting
First Posted : October 1, 2018
Last Update Posted : September 4, 2019
Sponsor:
Information provided by (Responsible Party):
Patrice Chevallier, Nantes University Hospital

Brief Summary:

Recent advances in acute myeloid leukemia (AML) have been characterized by a better understanding of disease biology. As such, FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) have been recognized as conferring a poor prognosis. The FLT3-ITD molecular mutation is observed in about one-quarter of patients diagnosed with AML. Patients presenting with this abnormality are referred for early allogeneic stem-cell transplantation (allo-SCT). However, some data suggest that FLT3-ITD remains associated with a poor prognosis even after allo-SCT because of higher risk of relapse and strategies for preventing relapse in the post-transplant setting are required (Hu et al, Expert Rev Hematol, 2014). For example, in a large cohort of patients (Brunet et al, JCO, 2012), the incidence of relapse for FLT3-ITD AML patients after allo-SCT was 30% at 2-years, significantly higher compared to FLT3-ITD negative patients (p=0.006).

Ponatinib (Iclusig®) is an orally available, tyrosine kinase inhibitor with a unique binding mechanism allowing inhibition of BCR-ABL kinases, including those with the T315I point mutation. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α (PDGFRα). In vitro activity of ponatinib in AML has been already demonstrated (Gozgit et al, Mol Cancer Ther, 2011; Smith et al, Blood 2013). If some trials are on-going to test ponatinib alone or in combination with chemotherapy in FLT3-ITD AML (Clinical.trials.gov), no study is dedicated to the use of ponatinib in the post-transplant setting in order to prevent relapse in these patients.

The main goal of this study will be to determine the maximal tolerated dose (MDT) of ponatinib after allo-SCT in FLT3-ITD AML patients, then to investigate the efficacy of ponatinib in a larger cohort of patients


Condition or disease Intervention/treatment Phase
Leukemia, Myeloid, Acute Drug: Ponatinib 30 MG Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 77 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial."
Actual Study Start Date : December 12, 2018
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : May 2022


Arm Intervention/treatment
Experimental: Experimental
Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
Drug: Ponatinib 30 MG
Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient




Primary Outcome Measures :
  1. Relapse incidence at 2 years from transplant [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 2 years ]
    time interval from the graft (day 0) until the date of last follow-up or death

  2. Leukemia free survival [ Time Frame: 2 years ]
    time interval from the date of the graft (day 0) until the date of last follow-up, death or relapse

  3. Non-relapse mortality (NRM) [ Time Frame: day 100 ]
    incidence of mortality due to all causes except relapse after transplant, considering that cause of death for patients having relapsed but dying from another cause is relapse

  4. Acute and chronic GVHD [ Time Frame: 2 years ]
    NIH score

  5. Influence of Ponatinib on Immune reconstitution PB lymphocyte cells [ Time Frame: 1 years ]
    an immunophenotype of PB lymphocytes will be performed by flow cytometry at +3, +6, +9 and +12 months post-transplant to study the reconstitutions of CD3, CD4 and CD8 T cells, B and NK cells. The results will be expressed as absolute counts (Giga/L). We want to establish the potential influence of ponatinib on the reconstitution of these cells

  6. Inflence of Ponatinib on Chimerism of Donor peripheral blood and CD3 T cells [ Time Frame: 1 years ]
    Donor peripheral blood and CD3 T cells chimerism will be studied using molecular markers and RT-PCR at day +30, +60, +90, and +6, +12 months post-transplant. We want to establish the potential influence of ponatinib on the chimerism post-transplant.

  7. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Engraftment
  • Controlled GVHD
  • Positive FLT-3 ITD AML in cytologic complete remission
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status < 2
  • Have adequate renal function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) for institution
  • Have adequate hepatic function: Total serum bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome; Alanine aminotransferase (ALT) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic infiltration of the liver is present ; Aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic infiltration of the liver is present
  • Have normal pancreatic status: Serum lipase and amylase ≤ 1.5 × ULN
  • Have normal QTcF interval on screening electrocardiogram (ECG) evaluation,defined as QTcF of ≤ 450 ms in males or ≤ 470 ms in females.
  • Platelets ≥ 100 Giga/l; Neutrophils ≥ 1 Giga/l
  • Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).
  • Agree to use an effective form of contraception with sexual partners throughout study participation (for female and male patients who are fertile).
  • Provide written informed consent.
  • Be willing and able to comply with scheduled visits and study procedures.

Exclusion Criteria:

  • HIV positive, active Hepatitis B or C
  • Childbearing or childbreast feeding women
  • Women or men without effective contraceptive barrier if needed
  • Previous myocardial infarction, or cerebral vascular accident, pancreatitis
  • Respiratory insufficiency defined as DLCO <40% of the corrected value
  • Creatinine clearance ≤ 50ml/min
  • Contra-indication to ponatinib
  • Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Patients at high or very high risk of cardiovascular disease with any of the following

    1. Established cardiovascular disease Cardiac disease:

      • Congestive heart failure greater than class II NYHA or
      • Left ventricular ejection fraction (LVEF) < 50% or
      • Unstable angina (anginal symptoms at rest) or
      • New onset angina (began within the last 3 months) or
      • Myocardial infarction, coronary/peripheral artery disease, congestive heart failure, cerebrovascular accident including transient ischemic attack within the past 12 months or
      • History of thrombolic or embolic events Arrhythmias
      • Any history of clinically significant cardiac arrhythmias requiring anti-arrhythmic therapy.
    2. Diabetes Mellitus,
    3. Arterial Hypertension,

      • Uncontrolled hypertension defined as systolic blood pressure greater than 140 mmHg or diastolic pressure greater than 90 mmHg, despite optimal medical management and optimal measurement (http://www.has-sante.fr/portail/display.jsp?id=c_272459)
      • Any history of hypertension with
      • Hypertensive encephalopathy
      • Posterior leucoencephalopathy
      • Aortic or artery dissection
    4. Familial dysplipidemia.
    5. Taking medications that are known to be associated with Torsades de Pointes (see

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690115


Contacts
Layout table for location contacts
Contact: Laure MORISSET +33139239785 lmorisset@ch-versailles.fr

Locations
Layout table for location information
France
CHU Angers Recruiting
Angers, France
Contact: François         
CHu Brest Not yet recruiting
Brest, France
Contact: Guillerm         
CHU Caen Recruiting
Caen, France
Contact: Chantepie         
CHU Clermont Ferrand Not yet recruiting
Clermont Ferrand, France
Contact: Guieze         
CHU Grenoble Recruiting
Grenoble, France
Contact: Bulabois         
CHU Lille Not yet recruiting
Lille, France
Contact: Yakoub Agha         
CHU Limoges Recruiting
Limoges, France
Contact: Turlure         
Chevallier Recruiting
Nantes, France
Contact: Patrice Chevallier         
Hopital St Antoine Not yet recruiting
Paris, France
Contact: Mothy         
Hopital St Louis Recruiting
Paris, France
Contact: Regis Peffault de la tour         
CHu Lyon Not yet recruiting
Pierre-Bénite, France
Contact: Labussière         
CHU Poitiers Not yet recruiting
Poitiers, France
Contact: Maillard         
CRLC Toulouse Recruiting
Toulouse, France
Contact: Huynh         
CHU Nancy Not yet recruiting
Vandœuvre-lès-Nancy, France
Contact: Rubio         
Sponsors and Collaborators
Versailles Hospital

Layout table for additonal information
Responsible Party: Patrice Chevallier, MD, Nantes University Hospital
ClinicalTrials.gov Identifier: NCT03690115     History of Changes
Other Study ID Numbers: P1701_ PONALLO
First Posted: October 1, 2018    Key Record Dates
Last Update Posted: September 4, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Leukemia
Neoplasms by Histologic Type
Neoplasms
Ponatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action